Xilio Therapeutics revenue was $15.00M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q2 2025) ending on Jun 30, 2025 was $8.1M, up 175.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, XLO annual revenue was $6.3M, with Infinity% growth year-over-year.
XLO past revenue growth
How has XLO's revenue growth performed historically?
On Invalid Date, Xilio Therapeutics (NASDAQ: XLO) reported Q2 2025 revenue of $8.08 million up 242.98% year over year. In the same quarter last year, Xilio Therapeutics's revenue was $2.36 million.
What was Xilio Therapeutics's revenue in 2024?
Xilio Therapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $6.34 million, a Infinity% increase year over year.
How much does Xilio Therapeutics make in a day?
Based on Xilio Therapeutics annual revenue for the past five years, XLO makes an average of $3,476.16 per day.
What was Xilio Therapeutics's annual revenue growth in the past year?
As of Q3 2025, Xilio Therapeutics's revenue has grown 536.44% year over year. This is 387.2 percentage points higher than the US Biotechnology industry revenue growth rate of 149.24%. Xilio Therapeutics's revenue in the past year totaled $15.00 million.
How much does Xilio Therapeutics make in a year?
Xilio Therapeutics's revenue by year for the past five years is:
Xilio Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $6.34 million, a Infinity% increase year over year.
Xilio Therapeutics's annual revenue for Dec 31, 2023 was $0.00, a N/A decrease from 2022.
Xilio Therapeutics's annual revenue for 2022 was $0.00, a N/A decrease from 2021.
Xilio Therapeutics's annual revenue for 2021 was $0.00, a N/A decrease from 2020.
Xilio Therapeutics's annual revenue for 2020 was $0.00, a N/A decrease from 2019.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.